- Record: found
- Abstract: not found
- Article: not found
Melanoma drug wins US approval.
2011-03-31
Antibodies, Monoclonal, adverse effects, immunology, therapeutic use, Antigens, CD, Antineoplastic Agents, pharmacology, Antineoplastic Combined Chemotherapy Protocols, CTLA-4 Antigen, Clinical Trials as Topic, Drug Approval, Humans, Immunotherapy, methods, Melanoma, drug therapy, genetics, pathology, Proto-Oncogene Proteins B-raf, antagonists & inhibitors, Survival Analysis, United States, United States Food and Drug Administration
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Antibodies, Monoclonal,adverse effects,immunology,therapeutic use,Antigens, CD,Antineoplastic Agents,pharmacology,Antineoplastic Combined Chemotherapy Protocols,CTLA-4 Antigen,Clinical Trials as Topic,Drug Approval,Humans,Immunotherapy,methods,Melanoma,drug therapy,genetics,pathology,Proto-Oncogene Proteins B-raf,antagonists & inhibitors,Survival Analysis,United States,United States Food and Drug Administration
Antibodies, Monoclonal, adverse effects, immunology, therapeutic use, Antigens, CD, Antineoplastic Agents, pharmacology, Antineoplastic Combined Chemotherapy Protocols, CTLA-4 Antigen, Clinical Trials as Topic, Drug Approval, Humans, Immunotherapy, methods, Melanoma, drug therapy, genetics, pathology, Proto-Oncogene Proteins B-raf, antagonists & inhibitors, Survival Analysis, United States, United States Food and Drug Administration